← Back to Brewed Up Insights
₹2,500 cr

a year saved on cancer drugs if trade margins are capped

NPPA's cancer drug margin cap could save patients ₹2,500 crore a year

Economy No. 66 14 October 2026 · 2 min read

On 8 October 2026, India's drug price regulator, NPPA, took the first step towards capping how much distributors, chemists and hospital pharmacies can add to cancer drug prices. It expects patients to pay 20% to 70% less.

The government fixes the maximum price of 388 essential drugs, including 63 cancer drugs. Most other cancer drugs have no price ceiling. Of the ₹12,500 crore worth of cancer drugs sold annually in India, only ₹2,250 crore is covered by price ceilings.

The problem is what happens between the manufacturer and the patient. NPPA found that distributors and pharmacies add an average 170% to the manufacturer's price for cancer drugs without a price ceiling. Some mark-ups reach a whopping 700%.

Under the proposed rule, the total trade margin cannot exceed 30% of the final price. For a drug that costs ₹100 at the manufacturer, this could bring its price down from ₹270 to about ₹143.

India has tried this before. In 2019, a similar cap on 42 cancer drugs cut the prices of 526 brands by up to 91%, saving patients about ₹984 crore a year.

The proposed savings of ₹2,500 crore a year are an estimate, not a guaranteed outcome. The 70% reduction is the upper end, not the typical cut. The cap is not in force yet. An expert committee is expected to identify the drugs by 14 October 2026, after which NPPA must formally notify the rule.

NPPA's cap would cut a ₹270 cancer drug to ₹143

What a patient pays for a cancer drug its maker sells at ₹100, today and with NPPA's cap. The maker's ₹100 stays; the supply chain's share shrinks.

Stream chart of what a patient pays for a cancer drug its maker sells at ₹100. Today, with the average trade mark-up of 170%, the patient pays ₹270: ₹100 to the maker and ₹170 to distributors, chemists and hospital pharmacies. With NPPA's cap of a 30% trade margin on MRP, the patient pays ₹143: the maker's ₹100 and ₹43 for the supply chain. The example assumes the mark-up is counted from the maker's price; NPPA expects MRPs to fall 20% to 70%.

₹ A PATIENT PAYS FOR A DRUG ITS MAKER SELLS AT ₹100

Maker's priceTrade margin

Trade margin: what distributors, chemists and hospital pharmacies add to the maker's price. The example assumes the 170% average mark-up is counted from the maker's price. NPPA expects MRPs to fall 20% to 70%, depending on each drug's mark-up today.

NPPA, minutes of the 151st Authority meeting, 8 October 2026; worked example · Oct 2026

NPPA's cap would save ₹2,500 crore of ₹10,250 crore

What India spends each year on cancer drugs with no price limit. NPPA expects its cap to save about a quarter of it.

₹ CRORE A YEAR

  • Saved by the cap
  • Still spent
Bar of the ₹10,250 crore India spends each year on cancer drugs with no price limit: ₹2,500 crore, 24.4%, saved by NPPA's proposed cap, and ₹7,750 crore, 75.6%, still spent. Another ₹2,250 crore of cancer drugs already has a price limit. The saving depends on which drugs an expert committee lists, due 14 October 2026.

Another ₹2,250 crore of cancer drugs already has a price limit. The saving depends on which drugs an expert committee lists, due 14 October 2026.

NPPA, minutes of the 151st Authority meeting, 8 October 2026 · Oct 2026

Sources